Literature DB >> 8703326

Evaluating the dose to the contralateral breast when using a dynamic wedge versus a regular wedge.

C D Weides1, E C Mok, W C Chang, D O Findley, C A Shostak.   

Abstract

The incidence of secondary cancers in the contralateral breast after primary breast irradiation is several times higher than the incidence of first time breast cancer. Studies have shown that the scatter radiation to the contralateral breast may play a large part in the induction of secondary breast cancers. Factors that may contribute to the contralateral breast dose may include the use of blocks, the orientation of the field, and wedges. Reports have shown that the use of regular wedges, particularly for the medial tangential field, gives a significantly higher dose to the contralateral breast compared to an open field. This paper compares the peripheral dose outside the field using a regular wedge, a dynamic wedge, and an open field technique. The data collected consisted of measurements taken with patients, solid water and a Rando phantom using a Varian 2300CD linear accelerator. Ion chambers, thermoluminescent dosimeters (TLD), diodes, and films were the primary means for collecting the data. The measurements show that the peripheral dose outside the field using a dynamic wedge is close to that of open fields, and significantly lower than that of regular wedges. This information indicates that when using a medial wedge, a dynamic wedge should be used.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8703326     DOI: 10.1016/0958-3947(95)02011-x

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  1 in total

1.  Hybrid volumetric modulated arc therapy for hypofractionated radiotherapy of breast cancer: a treatment planning study.

Authors:  Alexander Venjakob; Michael Oertel; Dominik Alexander Hering; Christos Moustakis; Uwe Haverkamp; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2020-10-17       Impact factor: 3.621

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.